Literature DB >> 33513859

Potassium Channels and Their Potential Roles in Substance Use Disorders.

Michael T McCoy1, Subramaniam Jayanthi1, Jean Lud Cadet1.   

Abstract

Substance use disorders (SUDs) are ubiquitous throughout the world. However, much remains to be done to develop pharmacotherapies that are very efficacious because the focus has been mostly on using dopaminergic agents or opioid agonists. Herein we discuss the potential of using potassium channel activators in SUD treatment because evidence has accumulated to support a role of these channels in the effects of rewarding drugs. Potassium channels regulate neuronal action potential via effects on threshold, burst firing, and firing frequency. They are located in brain regions identified as important for the behavioral responses to rewarding drugs. In addition, their expression profiles are influenced by administration of rewarding substances. Genetic studies have also implicated variants in genes that encode potassium channels. Importantly, administration of potassium agonists have been shown to reduce alcohol intake and to augment the behavioral effects of opioid drugs. Potassium channel expression is also increased in animals with reduced intake of methamphetamine. Together, these results support the idea of further investing in studies that focus on elucidating the role of potassium channels as targets for therapeutic interventions against SUDs.

Entities:  

Keywords:  alcohol; cocaine; methamphetamine; opioids; pharmacotherapy

Year:  2021        PMID: 33513859     DOI: 10.3390/ijms22031249

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  2 in total

1.  Effect of Prenatal Opioid Exposure on the Human Placental Methylome.

Authors:  Kristyn N Borrelli; Elisha M Wachman; Jacob A Beierle; Elizabeth S Taglauer; Mayuri Jain; Camron D Bryant; Huiping Zhang
Journal:  Biomedicines       Date:  2022-05-17

Review 2.  Epigenetic Landscape of Methamphetamine Use Disorder.

Authors:  Jean Lud Cadet; Subramaniam Jayanthi
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.